{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=9", "query": { "condition": "Head Neck Cancer Squamous Cell Metastatic", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 598, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T13:59:26.256Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "SCCHN", "Pancreatic Cancer", "Esophageal SCC", "Metastatic Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Hormone Receptor-positive Breast Cancer", "Epithelial Ovarian Cancer", "Endometrial Cancer", "Tissue Factor-Expressing Solid Tumors" ], "interventions": [ { "name": "XB002", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 269, "start_date": "2021-06-07", "completion_date": "2025-03-10", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925284" }, { "nct_id": "NCT04052204", "title": "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "avelumab", "type": "DRUG" }, { "name": "Bempegaldesleukin", "type": "DRUG" }, { "name": "talazoparib", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-12-30", "completion_date": "2020-09-29", "has_results": true, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04052204" }, { "nct_id": "NCT03829436", "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Metastatic Castration Resistant Prostate Cancer", "Renal Cell Carcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple-Negative Breast Cancer", "Urothelial Carcinoma", "Cholangiocarcinoma", "GastroEsophageal Cancer", "Pancreatic Cancer", "Sarcoma" ], "interventions": [ { "name": "Part 1 TPST-1120", "type": "DRUG" }, { "name": "Part 2 TPST-1120 + nivolumab", "type": "DRUG" }, { "name": "Part 3 TPST-1120", "type": "DRUG" }, { "name": "Part 4 TPST-1120 + nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempest Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2019-03-20", "completion_date": "2022-09-07", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 11, "location_summary": "San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829436" }, { "nct_id": "NCT03746431", "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Endometrial Cancer", "Cervical Cancer", "Ovarian Cancer", "Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "HER2-negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Adrenocortical Carcinoma", "Uveal Melanoma" ], "interventions": [ { "name": "[111In]-FPI-1547 Injection", "type": "DRUG" }, { "name": "[225Ac]-FPI-1434 Injection multi-dose", "type": "DRUG" }, { "name": "FPI-1175 Infusion", "type": "BIOLOGICAL" }, { "name": "[225Ac]-FPI-1434 Injection single-dose", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fusion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-01-17", "completion_date": "2025-12-03", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 7, "location_summary": "Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746431" }, { "nct_id": "NCT04634825", "title": "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Neoplasms", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Enoblituzumab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Tebotelimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2021-03-17", "completion_date": "2022-07-29", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634825" }, { "nct_id": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors", "Colorectal Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer", "NSCLC", "HNSCC", "Head and Neck Squamous Cell Carcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "MCLA-158", "type": "DRUG" }, { "name": "MCLA-158 + Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "MCLA-158 + FOLFIRI", "type": "COMBINATION_PRODUCT" }, { "name": "MCLA-158 + FOLFOX", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Merus B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2018-05-02", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 31, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 25 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526835" }, { "nct_id": "NCT01931150", "title": "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cetuximab-induced Papulopustular (Acneiform) Rash Who Have", "Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Topical Dapsone 5% Gel", "type": "DRUG" }, { "name": "Moisturizer", "type": "OTHER" }, { "name": "oral antibiotics", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931150" }, { "nct_id": "NCT03474497", "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Megan Daly, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-05-20", "completion_date": "2026-02", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 2, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03474497" }, { "nct_id": "NCT02741570", "title": "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab/Erbitux", "type": "DRUG" }, { "name": "Cisplatin/Platinol", "type": "DRUG" }, { "name": "Carboplatin/Paraplatin", "type": "DRUG" }, { "name": "Fluorouracil/Adrucil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 947, "start_date": "2016-10-05", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • Stanford, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02741570" }, { "nct_id": "NCT01469546", "title": "Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Axitinib (AG-013736)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2012-01", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2016-08-29", "last_synced_at": "2026-10-24T13:59:26.256Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01469546" } ] }